Artículos de revistas
Effects Of Pde Type 5 Inhibitors On Left Ventricular Diastolic Dysfunction In Resistant Hypertension
Registro en:
Arquivos Brasileiros De Cardiologia. Arquivos Brasileiros De Cardiologia, v. 104, n. 1, p. 85 - 89, 2015.
0066782X
10.5935/abc.20140159
2-s2.0-84923620742
Autor
de Faria A.P.C.
Modolo R.
Moreno B.V.D.
Moreno H.
Institución
Resumen
Resistant hypertension (RHTN) is a multifactorial disease characterized by blood pressure (BP) levels above goal (140/90 mmHg) in spite of the concurrent use of three or more antihypertensive drugs of different classes. Moreover, it is well known that RHTN subjects have high prevalence of left ventricular diastolic dysfunction (LVDD), which leads to increased risk of heart failure progression. This review gathers data from studies evaluating the effects of phosphodiesterase-5 (PDE-5) inhibitors (administration of acute sildenafil and short-term tadalafil) on diastolic function, biochemical and hemodynamic parameters in patients with RHTN. Acute study with sildenafil treatment found that inhibition of PDE-5 improved hemodynamic parameters and diastolic relaxation. In addition, short-term study with the use of tadalafil demonstrated improvement of LVDD, cGMP and BNP-32 levels, regardless of BP reduction. No endothelial function changes were observed in the studies. The findings of acute and short-term studies revealed potential therapeutic effects of IPDE-5 drugs on LVDD in RHTN patients. 104 1 85 89 Calhoun, D.A., Jones, D., Textor, S., Goff, D.C., Murphy, T.P., Toto, R.D., Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research (2008) Hypertension, 51 (6), pp. 1403-1419 Persell, S.D., Prevalence of resistant hypertension in the United States, 2003-2008 (2011) Hypertension, 57 (6), pp. 1076-1080 Pimenta, E., Calhoun, D.A., Resistant hypertension: Incidence, prevalence, and prognosis (2012) Circulation, 125 (13), pp. 1594-1596 Faria, A.P., Sabbatini, A.R., Coca, A., Moreno, H., Phenotypic characteristics of resistant hypertension in the Brazilian population (2013) Arq Bras Cardiol, 100 (6), pp. 579-582 Ubaid-Girioli, S., De Adriana Souza, L., Yugar-Toledo, J.C., Martins, L.C., Ferreira-Melo, S., Coelho, O.R., Aldosterone excess or escape: Treating resistant hypertension (2009) J Clin Hypertens (Greenwich), 11 (5), pp. 245-252 Arnal, J.F., El Amrani, A.I., Chatellier, G., Menard, J., Michel, J.B., Cardiac weight in hypertension induced by nitric oxide synthase blockade (1993) Hypertension, 22 (3), pp. 380-387 Pechanova, O., Bernatova, I., Pelouch, V., Babal, P., L-NAME-induced protein remodeling and fibrosis in the rat heart (1999) Physiol Res, 48 (5), pp. 353-362 Ferreira-Melo, S.E., Yugar-Toledo, J.C., Coelho, O.R., De Luca, I.M., Tanus-Santos, J.E., Hyslop, S., Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats (2006) Eur J Pharmacol, 542 (1-3), pp. 141-147 Ferreira-Melo, S.E., Demacq, C., Lacchini, S., Krieger, J.E., Irigoyen, M.C., Moreno, H., Sildenafil preserves diastolic relaxation after reduction by L-NAME and increases phosphodiesterase-5 in the intercalated discs of cardiac myocytes and arterioles (2011) Clinics (Sao Paulo), 66 (7), pp. 1253-1258 Solomon, S.D., Janardhanan, R., Verma, A., Bourgoun, M., Daley, W.L., Purkayastha, D., Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: A randomised trial (2007) Lancet, 369 (9579), pp. 2079-2087 Quinaglia, T., De Faria, A.P., Fontana, V., Barbaro, N.R., Sabbatini, A.R., Sertorio, J.T., Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension (2013) Eur J Clin Pharmacol, 69 (12), pp. 2027-2036 Santos, R.C., De Faria, A.P., Barbaro, N.R., Modolo, R., Ferreira-Melo, S.E., Matos-Souza, J.R., Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension (2014) Eur J Clin Pharmacol, 70 (2), pp. 147-154 Oliver, J.J., Melville, V.P., Webb, D.J., Effect of regular phosphodiesterase type 5 inhibition in hypertension (2006) Hypertension, 48 (4), pp. 622-627 Oliver, J.J., Hughes, V.E., Dear, J.W., Webb, D.J., Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension (2010) Hypertension, 56 (1), pp. 62-67. , Erratum in: Hypertension. 2012;60(1):e8 Jackson, G., Benjamin, N., Jackson, N., Allen, M.J., Effects of sildenafil citrate on human hemodynamics (1999) Am J Cardiol, 83 (5), pp. 13C-20C Nichols, D.J., Muirhead, G.J., Harness, J.A., Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality (2002) Br J Clin Pharmacol, 53 (1), pp. 5-12 Leite-Moreira, A.F., Correia-Pinto, J., Gillebert, T.C., Afterload induced changes in myocardial relaxation: A mechanism for diastolic dysfunction (1999) Cardiovasc Res, 43 (2), pp. 344-353 Brutsaert, D.L., Sys, S.U., Gillebert, T.C., Diastolic failure: Pathophysiology and therapeutic implications (1993) J am Coll Cardiol, 22 (1), pp. 318-325 Borlaug, B.A., Melenovsky, V., Marhin, T., Fitzgerald, P., Kass, D.A., Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans (2005) Circulation, 112 (17), pp. 2642-2649 Francis, S.H., Busch, J.L., Corbin, J.D., Sibley, D., CGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action (2010) Pharmacol Rev, 62 (3), pp. 525-563 Reffelmann, T., Kloner, R.A., Cardiovascular effects of phosphodiesterase 5 inhibitors (2006) Curr Pharm Des, 12 (27), pp. 3485-3494 Takimoto, E., Champion, H.C., Li, M., Belardi, D., Ren, S., Rodriguez, E.R., Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy (2005) Nat Med, 11 (2), pp. 214-222 Kass, D.A., Champion, H.C., Beavo, J.A., Phosphodiesterase type 5: Expanding roles in cardiovascular regulation (2007) Circ Res, 101 (11), pp. 1084-1095 Bishu, K., Hamdani, N., Mohammed, S.F., Kruger, M., Ohtani, T., Ogut, O., Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo (2011) Circulation, 124 (25), pp. 2882-2891 Westermann, D., Becher, P.M., Lindner, D., Savvatis, K., Xia, Y., Frohlich, M., Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II- induced heart failure in vivo (2012) Basic Res Cardiol, 107 (6), p. 308 Parekh, N., Maisel, A.S., Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure (2009) Curr Opin Cardiol, 24 (2), pp. 155-160 Yamaguchi, H., Yoshida, J., Yamamoto, K., Sakata, Y., Mano, T., Akehi, N., Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy (2004) J am Coll Cardiol, 43 (1), pp. 55-60 Lubien, E., Demaria, A., Krishnaswamy, P., Clopton, P., Koon, J., Kazanegra, R., Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparisonwith Doppler velocity recordings (2002) Circulation, 105 (5), pp. 595-601 Grewal, J., McKelvie, R., Lonn, E., Tait, P., Carlsson, J., Gianni, M., BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction (2008) Eur J Heart Fail, 10 (3), pp. 252-259 Sarafidis, P.A., Epidemiology of resistant hypertension (2011) J Clin Hypertens (Greenwich), 13 (7), pp. 523-528 Williams, B., Resistant hypertension: An unmet treatment need (2009) Lancet, 374 (9699), pp. 1396-1398 Redfield, M.M., Jacobsen, S.J., Burnett, J.C., Jr., Mahoney, D.W., Bailey, K.R., Rodeheffer, R.J., Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic (2003) JAMA, 289 (2), pp. 194-202 Rivas-Gotz, C., Khoury, D.S., Manolios, M., Rao, L., Kopelen, H.A., Nagueh, S.F., Time interval between onset of mitral inflow and onset of early diastolic velocity by tissue Doppler: A novel index of left ventricular relaxation: Experimental studies and clinical application (2003) J am Coll Cardiol, 42 (8), pp. 1463-1470 Guazzi, M., Vicenzi, M., Arena, R., Guazzi, M.D., PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: Results of a 1-year, prospective, randomized, placebo-controlled study (2011) Circ Heart Fail, 4 (1), pp. 8-17 Pierdomenico, S.D., Lapenna, D., Bucci, A., Di Tommaso, R., Di Mascio, R., Manente, B.M., Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension (2005) Am J Hypertens, 18 (11), pp. 1422-1428 De Souza, W.A., Sabha, M., De Faveri Favero, F., Bergsten-Mendes, G., Yugar-Toledo, J.C., Moreno, H., Intensive monitoring of adherence to treatment helps to identify “true” resistant hypertension (2009) J Clin Hypertens (Greenwich), 11 (4), pp. 183-191